FindTrial
Sign In

Vigabatrin

DRUG15 trials

Sponsors

Heidelberg University Hospital AöR, New York State Psychiatric Institute, NYU Langone Health, Catalyst Pharmaceuticals, Inc., National Institute on Drug Abuse (NIDA)

Conditions

AlcoholismCocaine AddictionCocaine DependenceComplex Partial SeizuresInfantile SpasmInfantile SpasmsNAFLDObesity

Phase 1

Vigabatrin Ph 1 Cocaine Interaction Study
CompletedNCT00626834
National Institute on Drug Abuse (NIDA)Cocaine Addiction
Start: 2008-02-29End: 2010-10-31Updated: 2017-01-12
Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder
CompletedNCT01585207
Barbara J. CoffeyTourette's Disorder
Start: 2012-07-31End: 2015-03-31Updated: 2018-01-19

Phase 2

Effects of Vigabatrin on Cocaine Self-Administration
TerminatedNCT00373581
New York State Psychiatric InstituteCocaine Dependence
Start: 2006-04-30End: 2006-12-31Updated: 2016-10-27
Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
CompletedNCT00527683
NYU Langone HealthCocaine Dependence
Start: 2007-04-30End: 2007-11-30Updated: 2008-04-11
Vigabatrin for Treatment of Cocaine Dependence
CompletedNCT00611130
Catalyst Pharmaceuticals, Inc.Cocaine Dependence
Start: 2008-01-31End: 2012-10-31Updated: 2016-04-13
Vigabatrin for the Treatment of Cocaine Dependency
CompletedNCT01281202
Catalyst Pharmaceuticals, Inc.Cocaine Addiction, Cocaine Dependence
Start: 2011-01-31End: 2012-12-31Updated: 2016-05-18
Vigabatrin for Cocaine and Alcohol Dependence
TerminatedNCT01335867
University of PennsylvaniaAlcoholism, Cocaine Dependence
Start: 2011-04-30End: 2013-12-31Updated: 2019-09-06
Vigabatrin and Insulin Sensitivity
CompletedNCT04321395
Washington University School of MedicineNAFLD, Obesity
Start: 2021-08-23End: 2024-05-15Updated: 2025-01-14
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
RecruitingNCT04987463
Katarzyna KotulskaTuberous Sclerosis Complex
Start: 2021-05-07End: 2026-03-31Target: 60Updated: 2024-02-08
Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)
RecruitingCTIS2022-502332-39-00
Heidelberg University Hospital AöRTuberous sclerosis complex (TSC)
Start: 2023-11-15Target: 64Updated: 2025-08-25

Phase 3

Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
WithdrawnNCT02299115
The Hospital for Sick ChildrenInfantile Spasms
Start: 2017-09-05End: 2019-03-06Updated: 2019-11-14
A Novel Approach to Infantile Spasms
SuspendedNCT03347526
University of Colorado, DenverInfantile Spasm
Start: 2018-04-19End: 2021-08-31Target: 394Updated: 2021-05-27
A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms
TerminatedNCT03421496
Radius Pharmaceuticals, Inc.Infantile Spasm
Start: 2018-09-05End: 2019-05-29Updated: 2023-06-07

Phase 4

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients
TerminatedNCT01266291
University of PennsylvaniaComplex Partial Seizures
Start: 2010-08-31End: 2013-12-31Updated: 2017-07-12
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
WithdrawnNCT01413711
Lundbeck LLCInfantile Spasms
Start: 2012-06-30Updated: 2012-09-13

Related Papers

Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT), a two-arm, randomized, observer-blind, controlled phase IIb national multicentre clinical trial: study protocol.
2025-01-064 citations
A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.
2013-06-0131 citations